

05-18-05

JC06 Rec'd PCT/PTO 16 MAY 2005

1645
PCT

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

10/525986

Express Mail Mailing Label
No.: EV 478 459 210 US
Date of Deposit: May 16, 2005

Appl. No. : 10/525,986
Applicant : Tadashi NAKAJIMA et al
Filed : Concomitantly herewith
For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
PROSTAGLANDIN
Art Unit : 1645
Docket No. : 05116/HG
Customer No.: 01933
Confirm. No.: 5004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lori Valdes
Lori Valdes

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

This application is a United States national phase application of International application PCT/JP2003/011004.

A copy of the International Search Report for PCT/JP2003/011004 was filed on February 25, 2005.

Submitted herewith are the following:

(1) copies of the publications cited in the International Search Report for PCT/JP2003/011004;

(2) a copy of EP 1 034 793 which is a family member of WO 00/09162, which was cited in said International Search Report;

BEST AVAILABLE COPY


(3) a copy of EP 0 956 865 which is a family member of WO 98/06433, which was cited in said International Search Report;

(4) copies of publications described on page 2 of the present specification; and

(5) Forms PTO/SB/08A and PTO/SB/08B.

It is respectfully requested that initialed copies of the Forms PTO/SB/08A and PTO/SB/08B be returned to the undersigned to indicate that the publications listed therein have been considered and made of record.

Respectfully submitted,



RICHARD S. BARTH
Reg. No. 28,180

Frishauf, Holtz, Goodman
& Chick, P.C.
767 Third Ave., 25th floor
New York, NY 10017-2023
Telephone: (212) 319-4900
Facsimile: (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM

RSB/lpv

Enc.: Forms PTO/SB/08A and PTO/SB/08B and copies of publications cited therein

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number

10/525,986

Filing Date

February 25, 2005

First Named Inventor

Tadashi NAKAJIMA

Group Art Unit

1645

Examiner Name

Sheet

1

of

3

Attorney Docket Number

05116/HG

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

FOREIGN PATENT DOCUMENTS

Exam Inits*	Cite No ¹	offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
/S.B./		EP	286903	A1	TRUSTEES OF COLUMBIA UNIV.	10-19-1988		
/S.B./		WO	90/02553	A1	PHARMACIA AB	03-22-1990		
/S.B./		EP	308135	A2	K.K. UENO SEIYAKU	03-22-1989		
/S.B./		WO	94/06433	A1	ALLERGEN, INC.	03-31-1994		
/S.B./		EP	639563	A2	ALCON LAB. INC.	02-22-1995		
/S.B./		WO	00/09162	A1	SENJU PHARM. CO.	02-24-2000		
/S.B./		WO	98/06433	A1	YOSHITOMI PHARM.	02-19-1998		
/S.B./		WO	97/23222	A1	ALCON LAB. INC.	07-03-1997		
/S.B./		EP	1 034 793	A1	SENJU PHARM. CO.	09-13-2000		*
/S.B./		EP	0 956 865	A1	YOSHITOMI PHARM.	11-17-1999		**

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: **May 16, 2005**


- * EP 1 034 793 is a family member of WO 00/09162.
- ** EP 0 956 865 is a family member of WO 98/06433.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	10/525,986		
		Filing Date	February 25, 2005		
		First Named Inventor	Tadashi NAKAJIMA		
		Group Art Unit	1645		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	05116/HG

U.S. PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
/S.B./		4,952,581		BITO et al	08-28-1990	

FOREIGN PATENT DOCUMENTS

Exam Inits ¹	Cite No ¹	offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
		JP	2726672	B2	TRUSTEES OF COLUMBIA UNIV.	05-12-1997		*
/S.B./		WO	02/38158	A1	PHARMACIA AB	05-16-2002		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: **May 16, 2005**

* USP 4,952,581 is a family member of JP 2726672

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				Application Number	10/525,986
				Filing Date	February 25, 2005
				First Named Inventor	Tadashi NAKAJIMA
				Group Art Unit	1645
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	05116/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²				
/S.B./		Megumi HONJO et al., "Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility", <u>Invest. Ophthalmol. & Vis. Sci.</u> , 42(1), 137-144 (2001).					
/S.B./		P. Vasantha RAO et al., "Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632", <u>Invest. Ophthalmol. & Vis. Sci.</u> , 42(5), 1029-1037 (2001).					
<table border="1"> <tr> <td>Examiner Signature</td> <td>/Sean Basquill/</td> <td>Date Considered</td> <td>07/16/2008</td> </tr> </table>				Examiner Signature	/Sean Basquill/	Date Considered	07/16/2008
Examiner Signature	/Sean Basquill/	Date Considered	07/16/2008				

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: May 16, 2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.B./